Developer docs
API playgroundTry for free, no card

Search company profiles

Direct Biologics

Full company profile

uuid0000t25

Namestring
Direct Biologics
Legal namestring
Direct Biologics
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Direct Biologics is a privately held clinical-stage biopharmaceutical company founded in 2017 in Austin, Texas, developing investigational secretome-based biologic product candidates derived from adult bone marrow mesenchymal stem cells (MSCs). The company's core platform, branded "Natural Intelligence™," leverages MSC-derived extracellular vesicle (EV)-enriched secretome manufactured under current Good Manufacturing Practice (cGMP) standards, combined with AI-enabled multi-omics analyses for proteomic and transcriptomic characterization. Its lead product candidate, ExoFlo (also designated DB-2Q), is being evaluated in a Phase III clinical trial for Acute Respiratory Distress Syndrome (ARDS), including both COVID-19-associated and Classic ARDS indications, and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2022.

The company's pipeline extends into inflammatory bowel disease, with DB-3Q in Phase IB/IIA development for perianal fistulizing Crohn's disease and additional Phase I/II programs for medically refractory Crohn's disease and ulcerative colitis (DB-3Y). Direct Biologics also commercialized a cGMP product in 2019 under FDA's HCT/P 361 tissue regulations. The company holds 9 issued patents globally with 81 pending applications, and operates from Austin, Texas with a Quality Control and R&D laboratory facility in San Diego, California opened in 2024.

Direct Biologics has no FDA-approved products and generates no disclosed commercial product revenue; the company's economics are funded by approximately $116M in cumulative disclosed private funding across five rounds from 2018 through 2022. Its customer base is exclusively clinical trial sites and patient populations enrolled in investigational studies, and pricing is not publicly disclosed because all candidates remain investigational.

Short descriptiontext

Direct Biologics is a privately held clinical-stage biotech developing MSC-derived secretome-based biologic candidates led by ExoFlo for ARDS and inflammatory bowel disease indications, advancing through Phase III trials under FDA RMAT designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative biologics, exosome therapeutics, stem cell secretome, cGMP manufacturing, clinical stage biopharmaceuticals
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Biologics
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Direct Biologics develops investigational, secretome-based biologic product candidates derived from adult bone marrow mesenchymal stem cells, manufactured under cGMP standards for use in clinical research. Its lead candidate ExoFlo is being studied in clinical trials for Acute Respiratory Distress Syndrome (ARDS), Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis. The company's pipeline assets are designated DB-2Q, DB-3Q, and DB-3Y across multiple clinical phases. All products are investigational and have not been approved by the FDA.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Direct Biologics is a biopharmaceutical company developing investigational secretome-based biologics. The company's core platform is Natural Intelligence™, which leverages mesenchymal stem cell (MSC)-derived secretome and extracellular vesicle (EV)-enriched products manufactured under cGMP standards. The primary product candidate is ExoFlo, which is in clinical development for Acute Respiratory Distress Syndrome (ARDS), Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis. The company's pipeline includes multiple investigational products designated DB-2Q, DB-3Q, and DB-3Y across various phases of clinical trials. These products are investigational and have not been approved by the FDA.

Product and service4 records
1ExoFlo
CategoryInvestigational secretome-based biologic (lead product candidate)
Description

ExoFlo is Direct Biologics' lead investigational exosome-based secretome product candidate derived from adult bone marrow mesenchymal stem cells, currently in clinical development for acute respiratory distress syndrome (ARDS) and additional indications including Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis.

2DB-2Q
CategoryInvestigational secretome-based biologic (ARDS indication)
Description

Investigational product candidate in Phase III clinical development for Acute Respiratory Distress Syndrome (ARDS), including COVID-19 associated ARDS and Classic ARDS. Holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation for COVID-19 associated ARDS.

3DB-3Q
CategoryInvestigational secretome-based biologic (Crohn's Disease indications)
Description

Investigational product candidate in Phase IB/IIA clinical study for Perianal Fistulizing Crohn's Disease and Phase I/II trials for Medically Refractory Crohn's Disease.

4DB-3Y
CategoryInvestigational secretome-based biologic (Ulcerative Colitis indication)
Description

Investigational product candidate in Phase I/II clinical trials for Medically Refractory Ulcerative Colitis.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Clinical-stage biotech developing exosome-based therapeutics (CAP-1002 and derivative exosome programs) for inflammatory and rare disease indications. Direct comparable as both companies leverage extracellular vesicle technology derived from cellular sources for clinical applications.

TypeDirect peer
Description

Commercial-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies for inflammatory conditions including ARDS and graft-versus-host disease. Highly comparable given shared MSC platform foundation and overlapping ARDS indication.

3Pluristem Therapeutics
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing placenta-derived MSC therapies for inflammatory and ischemic conditions. Comparable as a stem cell-derived biologic platform targeting similar inflammatory indications.

TypeDirect peer
Description

Clinical-stage biotech engineering extracellular vesicles/exosomes as targeted therapeutics for rare diseases and inflammatory conditions. Closely comparable exosome engineering platform and therapeutic development model.

TypeDirect peer
Description

Clinical-stage cellular therapeutics company developing placental-derived MSC and other cell-based therapies for cancer, autoimmune, and degenerative diseases. Comparable regenerative medicine platform and stem cell-derived therapeutic approach.

6Athersys
TypeDirect peer
Description

Clinical-stage regenerative medicine company developing MultiStem cell therapy for ARDS, stroke, and inflammatory conditions. Directly comparable given shared ARDS indication and stem cell-based therapeutic approach.

TypeEmerging player
Description

Clinical-stage biotech developing RNA-based therapeutics and cell therapy approaches for inflammatory and rare diseases. Comparable as an emerging player in advanced biologics with overlapping inflammatory disease focus.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharmaceutical company with established IBD franchise (Zeposia for UC, multiple Crohn's programs) and respiratory therapeutic portfolios. Relevant incumbent competing for the same end markets with broader commercial capabilities.

TypeBroad incumbent
Description

Global biopharmaceutical company dominating IBD treatment with Humira, Skyrizi, and Rinvoq franchises. Critical incumbent whose commercial scale and formulary access represent the primary competitive barrier for Direct Biologics' IBD pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Direct Biologics

Regenerative Biologicsdirectbiologics.com

Direct Biologics is a privately held clinical-stage biotech developing MSC-derived secretome-based biologic candidates led by ExoFlo for ARDS and inflammatory bowel disease indications, advancing through Phase III trials under FDA RMAT designation.

What Direct Biologics does

Direct Biologics is a privately held clinical-stage biopharmaceutical company founded in 2017 in Austin, Texas, developing investigational secretome-based biologic product candidates derived from adult bone marrow mesenchymal stem cells (MSCs). The company's core platform, branded "Natural Intelligence™," leverages MSC-derived extracellular vesicle (EV)-enriched secretome manufactured under current Good Manufacturing Practice (cGMP) standards, combined with AI-enabled multi-omics analyses for proteomic and transcriptomic characterization. Its lead product candidate, ExoFlo (also designated DB-2Q), is being evaluated in a Phase III clinical trial for Acute Respiratory Distress Syndrome (ARDS), including both COVID-19-associated and Classic ARDS indications, and received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2022.

The company's pipeline extends into inflammatory bowel disease, with DB-3Q in Phase IB/IIA development for perianal fistulizing Crohn's disease and additional Phase I/II programs for medically refractory Crohn's disease and ulcerative colitis (DB-3Y). Direct Biologics also commercialized a cGMP product in 2019 under FDA's HCT/P 361 tissue regulations. The company holds 9 issued patents globally with 81 pending applications, and operates from Austin, Texas with a Quality Control and R&D laboratory facility in San Diego, California opened in 2024.

Direct Biologics has no FDA-approved products and generates no disclosed commercial product revenue; the company's economics are funded by approximately $116M in cumulative disclosed private funding across five rounds from 2018 through 2022. Its customer base is exclusively clinical trial sites and patient populations enrolled in investigational studies, and pricing is not publicly disclosed because all candidates remain investigational.

Direct Biologics firmographics

Firmographics
Name
Direct Biologics
Legal name
Direct Biologics
Website
https://directbiologics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Direct Biologics is a privately held clinical-stage biotech developing MSC-derived secretome-based biologic candidates led by ExoFlo for ARDS and inflammatory bowel disease indications, advancing through Phase III trials under FDA RMAT designation.
Ownership category
akta.pro rank

Direct Biologics industry classification

Industry
Product category
Regenerative Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Regenerative biologics
  • Exosome therapeutics
  • Stem cell secretome
  • CGMP manufacturing
  • Clinical stage biopharmaceuticals

Where Direct Biologics is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Direct Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Direct Biologics product offering

Product offering

Core offering

Direct Biologics develops investigational, secretome-based biologic product candidates derived from adult bone marrow mesenchymal stem cells, manufactured under cGMP standards for use in clinical research. Its lead candidate ExoFlo is being studied in clinical trials for Acute Respiratory Distress Syndrome (ARDS), Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis. The company's pipeline assets are designated DB-2Q, DB-3Q, and DB-3Y across multiple clinical phases. All products are investigational and have not been approved by the FDA.

Product overview

Direct Biologics is a biopharmaceutical company developing investigational secretome-based biologics. The company's core platform is Natural Intelligence™, which leverages mesenchymal stem cell (MSC)-derived secretome and extracellular vesicle (EV)-enriched products manufactured under cGMP standards. The primary product candidate is ExoFlo, which is in clinical development for Acute Respiratory Distress Syndrome (ARDS), Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis. The company's pipeline includes multiple investigational products designated DB-2Q, DB-3Q, and DB-3Y across various phases of clinical trials. These products are investigational and have not been approved by the FDA.

Differentiator

Problem solved

Functional benefit

Products and services

  • ExoFlo ExoFlo is Direct Biologics' lead investigational exosome-based secretome product candidate derived from adult bone marrow mesenchymal stem cells, currently in clinical development for acute respiratory distress syndrome (ARDS) and additional indications including Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis.
  • DB-2Q Investigational product candidate in Phase III clinical development for Acute Respiratory Distress Syndrome (ARDS), including COVID-19 associated ARDS and Classic ARDS. Holds FDA Regenerative Medicine Advanced Therapy (RMAT) designation for COVID-19 associated ARDS.
  • DB-3Q Investigational product candidate in Phase IB/IIA clinical study for Perianal Fistulizing Crohn's Disease and Phase I/II trials for Medically Refractory Crohn's Disease.
  • DB-3Y Investigational product candidate in Phase I/II clinical trials for Medically Refractory Ulcerative Colitis.

Companies that use Direct Biologics

Customer profile

Segments3 records

Ideal customer profiles3 records

Direct Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Direct Biologics partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights4 records

Direct Biologics competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (CAP-1002 and derivative exosome programs) for inflammatory and rare disease indications. Direct comparable as both companies leverage extracellular vesicle technology derived from cellular sources for clinical applications.
  • Mesoblast: Commercial-stage cell therapy company developing mesenchymal stem cell (MSC)-based therapies for inflammatory conditions including ARDS and graft-versus-host disease. Highly comparable given shared MSC platform foundation and overlapping ARDS indication.
  • Pluristem Therapeutics: Clinical-stage regenerative medicine company developing placenta-derived MSC therapies for inflammatory and ischemic conditions. Comparable as a stem cell-derived biologic platform targeting similar inflammatory indications.
  • Evox Therapeutics: Clinical-stage biotech engineering extracellular vesicles/exosomes as targeted therapeutics for rare diseases and inflammatory conditions. Closely comparable exosome engineering platform and therapeutic development model.
  • Celularity Inc. Clinical-stage cellular therapeutics company developing placental-derived MSC and other cell-based therapies for cancer, autoimmune, and degenerative diseases. Comparable regenerative medicine platform and stem cell-derived therapeutic approach.
  • Athersys: Clinical-stage regenerative medicine company developing MultiStem cell therapy for ARDS, stroke, and inflammatory conditions. Directly comparable given shared ARDS indication and stem cell-based therapeutic approach.

Emerging players

  • Arcturus Therapeutics: Clinical-stage biotech developing RNA-based therapeutics and cell therapy approaches for inflammatory and rare diseases. Comparable as an emerging player in advanced biologics with overlapping inflammatory disease focus.

Broad incumbents

  • Bristol Myers Squibb: Large pharmaceutical company with established IBD franchise (Zeposia for UC, multiple Crohn's programs) and respiratory therapeutic portfolios. Relevant incumbent competing for the same end markets with broader commercial capabilities.
  • AbbVie: Global biopharmaceutical company dominating IBD treatment with Humira, Skyrizi, and Rinvoq franchises. Critical incumbent whose commercial scale and formulary access represent the primary competitive barrier for Direct Biologics' IBD pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Direct Biologics social profiles

Digital presence

Direct Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Direct Biologics leadership team

Management profile

Number of profiles

Profiles6 records

Direct Biologics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Direct Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Direct Biologics

What does Direct Biologics do?

Direct Biologics develops investigational, secretome-based biologic product candidates derived from adult bone marrow mesenchymal stem cells, manufactured under cGMP standards for use in clinical research. Its lead candidate ExoFlo is being studied in clinical trials for Acute Respiratory Distress Syndrome (ARDS), Perianal Fistulizing Crohn's Disease, Medically Refractory Crohn's Disease, and Medically Refractory Ulcerative Colitis. The company's pipeline assets are designated DB-2Q, DB-3Q, and DB-3Y across multiple clinical phases. All products are investigational and have not been approved by the FDA.

Is Direct Biologics a public or private company?

Direct Biologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Direct Biologics founded?

Direct Biologics was founded in 2017. It employs 51 to 100 people.

Where is Direct Biologics based?

Direct Biologics is headquartered in Austin, United States, in the North America region.

Who are Direct Biologics's main competitors?

Direct peers on record are Capricor Therapeutics, Mesoblast, Pluristem Therapeutics, Evox Therapeutics, Celularity Inc. and Athersys. Arcturus Therapeutics is listed as an emerging player. Broad incumbents are Bristol Myers Squibb and AbbVie.

Does Direct Biologics have an API?

No public API is recorded for Direct Biologics.

What industry is Direct Biologics in?

Direct Biologics's product category is Regenerative Biologics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIACAE, Gastroenterology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogDirect Biologics to Support ARDS Alliance as Educational SponsorDirect Biologics provided an educational grant to ARDS Alliance to produce a webinar on extracellular vesicle science, secretome research, and investigational biologic approaches for ARDS. The program, independently developed and produced by ARDS Alliance, will feature a physician and a patient perspective, with the recording available later this year.Delveinsight5 Exosome Therapies in the Clinical PipelineDelveInsight has published an industry overview highlighting five exosome-based therapies currently in clinical development, including Deramiocel (Capricor Therapeutics/Nippon Shinyaku), ExoFlo (Direct Biologics), AGLE-102 (Aegle Therapeutics), BRE-AD01 (Brexogen), and ILB-202 (ILIAS Biologics). Capricor's Deramiocel for Duchenne muscular dystrophy has reached a critical milestone with an FDA PDUFA target date of August 22, 2026, following resumption of its Biologics License Application review. The article also profiles emerging developers such as Aruna Bio, NurExone Biologic, and VivaZome Therapeutics advancing exosome candidates for neurological conditions, while noting that no exosome-based therapy has yet received FDA approval.openPR.comAcute Respiratory Distress Syndrome Market: Epidemiology, Therapies, and Key Players | Veru Inc., Direct Biologics, Athersys, Healios, MediciNovaIn 2023, the US led the ARDS market among the 7MM with a valuation of $1.643 billion, accounting for 62% of new cases. The market is projected to grow at a 3.6% CAGR, driven by emerging therapies like Sabizabulin and ExoFlo.FrontiersExosomal biomarkers in leukemia: translational potential and regulatory challenges for precision medicine applicationsThis review article analyzes the translational potential of exosomal biomarkers for precision medicine in leukemia, highlighting their role as liquid biopsy tools for diagnosis and monitoring. It outlines current regulatory frameworks under the EMA and FDA, noting that while companies like Direct Biologics and United Therapeutics are advancing exosome therapeutics, most diagnostic applications remain in early validation phases. The text emphasizes ongoing European collaborative initiatives aimed at standardizing isolation methods to overcome clinical implementation challenges.BioinformantDirect Biologics Announces Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Clinical TrialDirect Biologics announced significant survival benefits for its therapeutic candidate ExoFlo™ in a Phase 2 clinical trial for hospitalized adults with COVID-19-associated acute respiratory distress syndrome (ARDS). The study, published in the journal CHEST, demonstrated an absolute risk reduction of 30.8% in mortality for patients receiving the higher dose compared to placebo, alongside a strong safety profile with no treatment-related adverse events. Based on these results and prior data, the FDA has granted regenerative medicine advanced therapeutic designation and authorized a Phase 3 trial.Clinical Trials ArenaDirect Biologics’ ExoFlo shows decreased mortality in Covid-19 patientsDirect Biologics announced positive Phase II trial data for its therapeutic product ExoFlo, showing significantly decreased 60-day mortality rates in hospitalized Covid-19 patients with moderate-to-severe acute respiratory distress syndrome (ARDS). The company is currently recruiting for a broader Phase III trial involving 320 subjects with ARDS from any underlying cause to further investigate the drug's efficacy. Previously, the US FDA granted ExoFlo regenerative medicine advanced therapy designation based on preliminary results.McguirewoodsFinding Irreparable Harm: 5th Circuit Vacates Refusal to Enter Preliminary InjunctionThe U.S. Court of Appeals for the 5th Circuit vacated a district court's refusal to grant a preliminary injunction in a trade secret lawsuit filed by Direct Biologics against former executive Adam McQueen and his new employer, Vivex Biologics. The appellate court ruled that the lower court failed to make particularized findings regarding irreparable harm and the difficulty of quantifying damages resulting from the alleged misappropriation of confidential information. This decision remands the case for reconsideration, emphasizing the need for specific evidence beyond mere breach of non-compete covenants.DealFlow's SPAC NewsletterGood Works II Acquisition Terminates $675M Direct Biologics DealGood Works II Acquisition has mutually terminated its proposed $675 million business combination with Direct Biologics, as disclosed in an 8-K filing. The decision cancels the deal originally announced in October, which included a minimum cash condition of $75 million and a concurrent private placement by Direct Biologics. The termination agreement includes standard mutual releases and covenants not to file suit.Special Purpose Acquisition Company (SPAC) NewsGood Works II Acquisition Corp. (GWII) Terminates Direct Biologics Deal|SPACInsiderGood Works II Acquisition Corp. has mutually terminated its combination agreement with drug developer Direct Biologics, ending a deal initially announced in late 2022 valued at $723 million. The termination follows significant shareholder redemptions that drained 89.24% of the SPAC's trust fund, leaving it with approximately $24.85 million.SecSEC FORM DThe Securities and Exchange Commission is notifying the public of an exempt offering of securities by Direct Biologics, LLC, based in Austin, Texas. The offering is made in connection with a proposed business combination transaction, with a total amount sold as of now being approximately $11.57 million. The issuer intends this offering to last less than one year and has not disclosed certain revenue figures.